key: cord-0908644-rmymhgv1 authors: Eldeeb, Mohamed A.; Hussain, Faraz S.; Siddiqi, Zaeem A. title: COVID-19 infection may increase the risk of parkinsonism – Remember the Spanish flu? date: 2020-06-07 journal: Cytokine Growth Factor Rev DOI: 10.1016/j.cytogfr.2020.06.009 sha: a9ee674ecaf0f27118eebd7e7617b789b70d021c doc_id: 908644 cord_uid: rmymhgv1 nan The recent outbreak of coronavirus disease 2019 (COVID-19) has resulted in a global pandemic. Crucially, most of the damage in patients dying from the COVID19 infection appears to be mediated by their own immune responses rather than by the virus. The viral infection culminates in a surge in signaling protein molecules that elicits massive inflammation, a "cytokine storm",which targets the lungs, attacking different tissues culminating in acute respiratory distress syndrome (ARDS), multiorgan failure and death [1] . The very high level of pro-inflammatory cytokines i.e. the cytokine storm, or cytokine release syndrome (CRS), may be pivotal in the severe pathology of COVID-19. The cytokine storm is not unique to COVID-19 but is also associated with influenza virus, human immune deficiency virus and some other viruses. Recent studies suggest a link between the cytokine storm, and speeding up the onset of Parkinson's [2, 3, 4] . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen for COVID-19, targets mainly the lung and other organs, culminating in organ damage via binding angiotensinconverting enzyme 2 (ACE2) receptor [5] , a highly expressed protein on the outer surface of cells within the lung, kidney and heart [6] . Notably, the massive release of inflammatory cytokines and chemokines during the "cytokine storm" may be crucial in mortality from COVID-19. Several inflammatory cytokines, such as interleukin-6 (IL-6) and interleukin-1β (IL-1β), are significantly elevated in COVID-19 patients, with some chemokines observed more in severely ill patients. Postmortem pathology, in COVID-19 patients with upregulated inflammatory chemokines, reveals necrosis and monocyte infiltrations in the lung, heart and gastrointestinal mucosa [7, 8] . Besides, severe lymphopenia with hyperactivated proinflammatory T cells [8] is widely observed in critically sick patients, suggesting a potent trigger of cytokine storm and dysfunctional immune responses. Although SARS-CoV-2 virus may cause neurological issues by eliciting immune cytokines storm, alternatively, it might directly infect the brain. Indeed, recent studies demonstrate the presence of the novel coronavirus in the post-mortem brain tissues of fatal cases of COVID-19 [9] . It has been suggested that infection of endothelial cells may facilitate the virus passage from the respiratory tract to the blood thereby crossing the blood-brain barrier into the brain. The hypothesis that a viral infection may trigger the onset of parkinsonism stems from a few previous observations [14] . First, the incidence of parkinsonism after the Spanish flu pandemic in 1918 increased significantly with people born during the pandemic having 2 to 3-fold risk to develop parkinsonism than those born before 1888 or after 1924 [14] . Notably, many of these patients that survived Spanish flu later exhibited viral encephalitis [15] . Viral encephalitis is brain swelling, inflammation and damage, which can take place upon viral infection of the central nervous system ultimately infecting the brain, a scenario which can be fatal. Indeed, almost every Spanish Influenza patient who had an acute episode of encephalitis (brain swelling within the infection course) from the influenza virus later developed the so-called Viral Parkinsonism. Since Interestingly, the dengue viral infection, which is an arbo viral infection transmitting by Aedes mosquitoes [16] and affects over 300 million infections per year with millions of severe cases, has been reported to progress to ultimately culminate in massive cytokine storm in severe dengue J o u r n a l P r e -p r o o f viral infection cases. While some patients can be recovered from primary symptoms of severe dengue-viral infection, the dengue viral-mediated cytokine storm and its potential consequent post encephalitic parkinsonism still exist after the dengue viral infection [17] . Although viral parkinsonism might bear similar features with idiopathic Parkinsonism, it seems unlikely that the pathophysiology is due to abnormal Lewy bodies accumulation and neurofibrillary deposition in brain tissue [14, 18] . Whether the dengue viral-mediated cytokine storm and the resultant augmented inflammatory reaction underly the molecular events leading to dengue-linked parkinsonism is far from clear. Nevertheless, as shown previously, immunosuppression steroids such as methylprednisolone aids in selected patients. Intriguingly, given that several recent reports support the notion that elevation of pro-inflammatory cytokines levels including IL-6 and IL-1β may hasten the onset of Parkinson's symptoms [2, 3, 19, 20] and, concomitant intake of non-steroidal anti-inflammatory medication is inversely associated with a later diagnosis of Parkinson's disease [21] . Since COVID-19 results in cytokine storm in many cases [22] , it is plausible that it may lead to an increased incidence of parkinsonism in those who recover from the infection. Future investigations and longitudinal studies are crucially advisable in this patient population to discern this possible risk. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Parkin and PINK1 mitigate STING-induced inflammation Intestinal infection triggers Parkinson's disease-like symptoms in Pink1−/− mice Plasma IL-6 and IL-17A correlate with severity of motor and non-motor symptoms in Parkinson's Disease A pneumonia outbreak associated with a new coronavirus of probable bat origin ACE2: from vasopeptidase to SARS virus receptor A pathological report of three COVID-19 cases by minimally invasive autopsies Pathological findings of COVID-19 associated with acute respiratory distress syndrome The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients Targeting α-synuclein for treating Parkinson's disease: mechanistic and therapeutic considerations Viral parkinsonism Viral encephalitis: causes, differential diagnosis, and management Cytokine signature associated with disease severity in Dengue Post encephalitic parkinsonism following dengue viral infection Post-dengue parkinsonism Interleukin 6 and complement serum level study in Parkinson's disease Aberrations in peripheral inflammatory cytokine levels in Parkinson Disease: A Systematic Review and Meta-analysis Meta-analysis of early nonmotor features and risk factors for Parkinson disease He has earned his PhD from the University of Alberta focusing on the N-end rule mediated protein degradation of kinases in cancer cells and its cellular ramifications on cancer cell death. He has joined the Montreal Neurological Institute to investigate the molecular mechanisms underlying neurodegeneration He received his postdoctoral training at the division of neurology Zaeem Siddiqi received his medicine training from Army medical college, Pakistan and earned a Ph.D. in Neurosciences from Boston University School of Medicine. He worked as Resident Neurology and Fellow Clinical Neurophysiology at Duke University Medical Center. Currently, He is a professor of Neurology and Director of Neuromuscular program at University of Alberta. His research interest are physiology and molecular pathology of neurological disorders with a specialization in neuromuscular disorders